List of Excipients in Branded Drug CHOLBAM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Manchester Pharmaceuticals LLC	CHOLBAM	cholic acid	45043-001	CELLULOSE, MICROCRYSTALLINE	1969-12-31
Manchester Pharmaceuticals LLC	CHOLBAM	cholic acid	45043-001	CROSPOVIDONE	1969-12-31
Manchester Pharmaceuticals LLC	CHOLBAM	cholic acid	45043-001	FERRIC OXIDE RED	1969-12-31
Manchester Pharmaceuticals LLC	CHOLBAM	cholic acid	45043-001	GELATIN	1969-12-31
Manchester Pharmaceuticals LLC	CHOLBAM	cholic acid	45043-001	MAGNESIUM STEARATE	1969-12-31
Manchester Pharmaceuticals LLC	CHOLBAM	cholic acid	45043-001	TITANIUM DIOXIDE	1969-12-31
Mirum Pharmaceuticals Inc	CHOLBAM	cholic acid	79378-001	CELLULOSE, MICROCRYSTALLINE	1969-12-31

CHOLBAM Excipient Strategy and Commercial Opportunities

Last updated: August 15, 2026

CHOLBAM is an orphan prescription product containing cholic acid for bile acid synthesis disorders caused by single-enzyme defects and for adjunctive treatment of peroxisomal disorders, including Zellweger spectrum disorders. Its commercial opportunity is driven by chronic treatment, pediatric use, limited alternatives and high switching costs, while its principal formulation opportunity is an age-appropriate, flexible dosage form with improved administration and dose accuracy. The current product is an immediate-release capsule with a relatively conventional excipient system.[1]

What is CHOLBAM and who markets it?

CHOLBAM contains synthetic cholic acid, a primary bile acid that replaces deficient endogenous bile acid activity and suppresses abnormal bile acid synthesis. The product was approved by the U.S. Food and Drug Administration in 2015 under NDA 205750.[2]

Attribute	CHOLBAM profile
Active ingredient	Cholic acid
Dosage forms	50 mg and 250 mg capsules
U.S. sponsor	Travere Therapeutics, following prior ownership by Asklepion Pharmaceuticals and Retrophin
FDA approval	February 18, 2015
Approved uses	Bile acid synthesis disorders caused by single-enzyme defects; adjunctive treatment of peroxisomal disorders
Regulatory category	Orphan drug; rare pediatric disease product
Administration	Oral, with food; capsule contents may be administered with soft food for patients unable to swallow capsules
Primary commercial segment	Pediatric and adult patients with ultra-rare metabolic disease

The product is supplied in two strengths, but patients may require individualized dosing based on body weight, age, diagnosis and biochemical response. That creates a commercial opening for dose-flexible formulations, provided the product retains the current clinical and regulatory profile.[1]

What excipients are used in CHOLBAM capsules?

The CHOLBAM capsule uses standard solid-dose excipients to support powder handling, capsule filling, disintegration and shell integrity. The U.S. prescribing information identifies the principal inactive ingredients as microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide and magnesium stearate. The capsule shell includes gelatin, titanium dioxide and coloring materials that vary by capsule strength.[1,3]

Excipient or component	Likely technical function	Commercial relevance
Microcrystalline cellulose	Diluent, carrier and compressibility aid for powder filling	Widely available; limited differentiation
Sodium starch glycolate	Superdisintegrant	Supports rapid capsule opening and dispersion
Colloidal silicon dioxide	Glidant and moisture-flow aid	Helps manage powder flow and fill-weight consistency
Magnesium stearate	Lubricant	Controls manufacturing friction; excessive use can affect wetting
Gelatin	Capsule shell polymer	Conventional but may create animal-origin, religious or dietary restrictions
Titanium dioxide	Opacifier	Subject to market-specific regulatory and customer preferences
Capsule colorants	Product identification	Important for pediatric acceptance and medication safety

The current formulation is commercially efficient because it uses established excipients and conventional capsule manufacturing. It is less differentiated from a generic-development perspective than a multiparticulate, liquid, dispersible or modified-release product.

How does CHOLBAM’s excipient system affect formulation performance?

Cholic acid is an amphiphilic bile acid rather than a conventional highly water-soluble small molecule. Formulation performance is therefore influenced by wetting, dispersion, particle size, food intake and interaction with the gastrointestinal environment. The product label instructs administration with food, which reduces the need for an aggressively solubilizing excipient system in the existing capsule.[1]

The current excipient strategy has four practical advantages:

1. It supports a low-complexity immediate-release product.
2. It minimizes the number of novel excipients requiring regulatory justification.
3. It is compatible with conventional capsule-filling equipment.
4. It supports opening the capsule and mixing the contents with soft food when swallowing is difficult.

The limitations are also clear. Powder handling can become difficult when the active has poor flow, broad particle-size distribution or static behavior. Magnesium stearate and hydrophobic capsule-fill components can reduce wetting if overused. Pediatric administration through soft food can introduce variability in dose recovery, taste, dispersion and caregiver technique.

What excipient strategies could improve CHOLBAM?

Pediatric sprinkle formulation

The most commercially relevant opportunity is a capsule or sachet containing coated granules or multiparticulates that can be sprinkled onto soft food. A sprinkle system could improve dose recovery, reduce clumping and provide more consistent dispersion than a loose powder.

Potential excipient classes include:

• Microcrystalline cellulose or dibasic calcium phosphate as inert cores.
• Hypromellose or ethylcellulose as coating polymers.
• Poloxamers or other wetting agents to improve dispersion.
• Low-level colloidal silicon dioxide for flow.
• Taste-masking polymers or lipid coatings to reduce bitterness.

The main regulatory challenge is maintaining rapid release and demonstrating comparable exposure to the current capsule. A coating that delays release or materially changes food interaction could create a new clinical and regulatory profile.

Lower-strength dosage forms

The two current capsule strengths may not provide optimal dose increments for small children. A 25 mg capsule, scored multiparticulate, oral powder or unit-dose sachet could improve titration and reduce the need to manipulate capsules.

A smaller strength could also reduce medication waste in weight-based dosing. The commercial value would depend on reimbursement, packaging cost and whether the new strength expands treated patients or simply shifts volume from 50 mg capsules.

Liquid or semi-solid formulation

An oral suspension, solution or lipid-based dispersion could simplify administration for infants and children. Cholic acid’s amphiphilic properties make lipid and surfactant systems technically plausible, but the formulation would require close control of:

• Dose uniformity after shaking.
• Sedimentation and redispersibility.
• Preservative compatibility.
• Microbial limits.
• Container adsorption.
• Chemical stability and oxidation.
• Taste and gastrointestinal tolerability.

A liquid product would have higher manufacturing and distribution costs than capsules. It could still command a premium if it materially improves adherence and enables treatment in children unable to swallow or reliably open capsules.

Vegetarian or regionally acceptable capsules

Replacing gelatin with hypromellose or another non-animal capsule shell could expand use in markets or patient populations that restrict gelatin. The change would require evaluation of moisture transmission, shell brittleness, fill compatibility, dissolution and stability.

This is a modest but practical commercial opportunity. It is more likely to support geographic expansion or lifecycle management than to create a strong U.S. exclusivity barrier.

Excipients that improve supply-chain resilience

A sponsor can reduce manufacturing risk by qualifying dual suppliers for microcrystalline cellulose, sodium starch glycolate, silicon dioxide and magnesium stearate. For an orphan product, inventory disruptions can have an outsized clinical and commercial impact because patient numbers are small and replacement products are limited.

The most important supply-chain controls are:

• Dual-source qualification for each critical excipient.
• Tight limits on moisture, peroxide value and particle size.
• Capsule-shell supplier redundancy.
• Separate controls for colorant availability.
• Long-term stability data under global climatic conditions.
• Compatibility studies for alternate grades and suppliers.

A supplier change that alters grade, particle size or surface treatment may require regulatory assessment even if the compendial name remains unchanged.

What formulation patents could protect a CHOLBAM follow-on product?

A conventional excipient substitution is unlikely to create a strong standalone patent position. Patentable opportunities are more likely to arise from a defined product architecture that delivers a measurable technical result.

Potential claim categories include:

Claim area	Possible protected subject matter
Multiparticulates	Cholic acid particles with defined size, coating thickness and release profile
Taste masking	Coated particles that reduce bitterness while preserving immediate release
Pediatric dosing	Unit-dose granules or sachets delivering defined dose increments
Liquid products	Stable suspensions with specified pH, preservative and redispersibility limits
Food administration	Formulations maintaining dose uniformity when mixed with specified foods
Manufacturing	Low-shear blending, granulation or coating processes that improve content uniformity
Stability	Formulations that limit degradation under heat or humidity
Combination therapy	Cholic acid with another bile-acid pathway agent, where clinically supported

The strongest formulation estate would combine composition claims, manufacturing claims and specific use claims. A patent that merely lists common excipients at broad concentration ranges would face greater validity and design-around risk.

Patent diligence should separate three categories:

1. Patents listed in the FDA Orange Book for the approved product.
2. Unlisted formulation, manufacturing and method-of-use patents.
3. Regulatory exclusivity, which is separate from patent protection.

The Orange Book remains the controlling public source for current U.S. product-specific patent listings and regulatory exclusivity information.[4] A third party developing a competing product must review the current listing rather than rely on historical patent summaries.

When does CHOLBAM lose exclusivity?

CHOLBAM received seven years of orphan-drug exclusivity beginning with the 2015 approval. That period was expected to end in February 2022, subject to any applicable pediatric extension or other regulatory event.[2,5]

Exclusivity type	CHOLBAM position
Orphan-drug exclusivity	Seven years from the 2015 approval
Pediatric exclusivity	Requires confirmation in current FDA records; may add six months where granted
New chemical entity exclusivity	Not the primary protection emphasized for this product
Patent protection	Must be assessed from current Orange Book and patent records
Market exclusivity after orphan period	Depends on patents, regulatory requirements, manufacturing capability and payer access

Expiration of orphan exclusivity does not guarantee immediate generic entry. A generic applicant still faces formulation development, product-specific regulatory requirements, patent certifications, physician familiarity, limited market scale and commercial manufacturing economics.

What is the Orange Book status of CHOLBAM?

The FDA Orange Book identifies approved products, therapeutic equivalence information and, where applicable, patent and exclusivity data. CHOLBAM’s strategic risk assessment should distinguish whether a patent is listed against the capsule product, dosage form, method of use or another product attribute.[4]

A Paragraph IV challenger would assert that a listed patent is invalid, unenforceable or not infringed. A generic applicant could also pursue a Paragraph III certification or wait for patent expiration. The commercial attractiveness of a Paragraph IV filing depends on the addressable patient population, expected price erosion, manufacturing cost and litigation expense.

For an ultra-rare product, a first generic may not produce the same level of volume as a mass-market drug. The reference sponsor can retain meaningful share through clinical familiarity, patient services, specialty-pharmacy distribution and supply reliability even after legal exclusivity ends.

Which companies could challenge CHOLBAM?

The most credible challengers are likely to be:

• Generic manufacturers with orphan-drug development capabilities.
• Specialty pharmaceutical companies active in metabolic disease.
• Compounding pharmacies serving individual patients.
• Developers of alternative bile-acid replacement or pathway-modifying products.
• Sponsors pursuing liquid or pediatric formulations rather than a direct capsule copy.

A direct generic capsule would face the lowest technical barrier. A pediatric liquid or sprinkle product could compete on administration and adherence while avoiding a direct price-only contest.

No biosimilar pathway applies because CHOLBAM contains a chemically synthesized small molecule, cholic acid, rather than a biologic. The relevant competitive pathways are ANDA, 505(b)(2), a new NDA or, outside the U.S., national generic and hybrid procedures.[6]

What commercial opportunities exist beyond a generic capsule?

Lifecycle management

The highest-value opportunity is a differentiated pediatric product. A sponsor could pursue:

• 25 mg and other lower-dose strengths.
• Sprinkle granules.
• Unit-dose sachets.
• A taste-masked formulation.
• A liquid or semi-solid dosage form.
• Vegetarian capsules.
• Packaging optimized for specialty-pharmacy dispensing.

A new dosage form could be submitted under a 505(b)(2) strategy if the sponsor can rely partly on existing CHOLBAM data while generating bridging studies. The regulatory route would depend on formulation differences, labeling claims and the extent of new clinical evidence required.[7]

Licensing and partnerships

Potential partners include excipient suppliers, capsule manufacturers, pediatric drug-delivery companies and specialty CDMOs. A licensing deal could focus on:

• Proprietary coating technology.
• Pediatric liquid platforms.
• Non-gelatin capsule systems.
• Low-moisture or high-containment manufacturing.
• Global commercialization rights.
• Regional distribution and regulatory registration.

The strongest deal structure would link development milestones to clinical or commercial performance, rather than licensing a generic excipient blend with limited defensibility.

Geographic expansion

Outside the United States, commercial opportunities depend on orphan designation, local pricing, reimbursement and the availability of cholic acid products. A regionally adaptable excipient strategy should account for:

• Gelatin restrictions.
• Titanium dioxide policies.
• Local food vehicles used for administration.
• Hot and humid stability conditions.
• Unit-dose packaging requirements.
• Local pharmacopoeial standards.

A formulation that uses common excipients may simplify registration, but it will not automatically secure market access. Pediatric acceptability and reimbursement evidence may be more important than formulation novelty.

How strong is the CHOLBAM patent and formulation estate?

CHOLBAM’s commercial protection is stronger as an orphan metabolic product than as a technically complex formulation. The conventional capsule architecture is potentially reproducible by a competent generic manufacturer. The more defensible assets are likely to be clinical positioning, physician experience, patient support, regulatory history, manufacturing know-how and any surviving method-of-use or formulation claims.

Asset	Relative strength
Conventional capsule formulation	Moderate to weak against a capable generic
Pediatric sprinkle formulation	Potentially strong if claims cover performance and administration
Liquid dosage form	Potentially differentiated but technically and regulatorily expensive
Method-of-use claims	Depends on claim scope, validity and remaining term
Manufacturing know-how	Useful operational barrier; difficult to enforce independently
Orphan clinical position	Strong commercial advantage but time-limited
Brand and specialty distribution	Potentially durable after patent expiry

What generic launch scenarios exist?

The likely launch scenarios are:

1. A direct capsule generic enters after resolving or avoiding listed patents.
2. A 505(b)(2) sponsor launches a differentiated pediatric dosage form.
3. A compounding-based alternative remains available for individual patients but does not achieve broad substitution.
4. The originator retains premium pricing through service, supply and physician familiarity.
5. A competing bile-acid or metabolic therapy reduces the addressable market.

The most important variable is not simply patent expiry. It is whether a challenger can achieve commercial scale in a small, medically specialized population while meeting manufacturing, reimbursement and distribution requirements.

Key Takeaways

• CHOLBAM is an orphan cholic acid product approved for rare bile acid synthesis and peroxisomal disorders.
• Its current capsule uses conventional excipients: microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate and gelatin-based shell components.
• The best formulation opportunity is a pediatric sprinkle, lower-strength or liquid dosage form.
• Common-excipient substitution alone is unlikely to create a durable patent position.
• A defensible lifecycle product should combine dose flexibility, taste masking, administration consistency and measurable stability or bioavailability advantages.
• CHOLBAM is a small-molecule drug, so biosimilar risk is not relevant.
• Generic entry risk depends on current Orange Book listings, remaining patent terms, ANDA strategy and the economics of an ultra-rare disease market.
• Commercial barriers include specialty distribution, physician familiarity, patient support and manufacturing reliability.
• Excipient suppliers and pediatric drug-delivery companies have the clearest partnership opportunities.

FAQs

Can CHOLBAM capsules be opened and mixed with food?

Yes. The prescribing information permits capsule contents to be administered with soft food for patients unable to swallow capsules. Administration should follow the approved product instructions to preserve dose consistency.[1]

Is a CHOLBAM liquid formulation commercially attractive?

Yes, particularly for infants and children, but the product would require extensive control of dose uniformity, sedimentation, taste, stability and microbial quality. A liquid could support lifecycle management but would have higher manufacturing and distribution costs.

Are there biosimilar competitors to CHOLBAM?

No. Cholic acid is a chemically synthesized small molecule. Potential competitors would use generic, 505(b)(2) or new-drug pathways rather than the biosimilar pathway.

Which excipients are most important for a CHOLBAM generic?

Microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide and magnesium stearate are the principal functional excipients in the capsule-fill system. Their grade, particle size, moisture and lubrication characteristics can affect content uniformity, dissolution and manufacturing performance.

Can an excipient supplier patent a CHOLBAM formulation?

Possibly, but the patent would need to claim a sufficiently specific composition, process or performance advantage. Broad claims covering standard excipients at routine concentrations would face substantial validity and design-around risks.

References

1. U.S. Food and Drug Administration. (2023). CHOLBAM (cholic acid) capsules: Prescribing information.
2. U.S. Food and Drug Administration. (2015). FDA approves Cholbam to treat rare, inherited liver disorders.
3. DailyMed. (n.d.). CHOLBAM- cholic acid capsule. National Library of Medicine.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity.
6. U.S. Food and Drug Administration. (2024). Generic drug facts and abbreviated new drug application requirements.
7. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).